Novel use of imidazotriazinones
CA 2491455 A1 · Owner: Bayer Healthcare Ag · Inventors: Bischoff, Erwin; Niewoehner, Ulrich (Deceased); Haning, Helmut
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to novel uses of imidazo1,2,4triazinones for producing a medicament for the treatment and/or prophylaxis of coronary cardiopathy heart failure, pulmonary hypertension, bladder complaints prostatic , hyperplasia, nitrate-induced tolerance or diseases of the eye, such as , glaucoma for the treatment or prophylaxis of central retinal or posterior , ciliary artery occlusion central retinal vein occlusion, optical neuropathy such as anterior ischaemic optical neuropathy and glaucomatous optical neuropathy, in addition to macular degeneration diabetes, in particular , diabetic gastroparesis for the treatment of dysperistalsis of the stomach and oesophagus, female …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 24, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 24, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 24, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.